J&J: promising study for HIV treatment
(CercleFinance.com) - On Saturday Janssen of Johnson & Johnson presented positive long-term data from a global phase 3b trial evaluating the first treatment regimen including two long-acting drugs, rilpivirin (from Janssen) and cabotegravir (from ViiV Healthcare) in the treatment of HIV infection in adults.
The results showed the effectiveness of monthly dosing as well as bimonthly dosing in adults with an undetectable viral load.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The results showed the effectiveness of monthly dosing as well as bimonthly dosing in adults with an undetectable viral load.
Copyright (c) 2021 CercleFinance.com. All rights reserved.